No products in the cart
Mod GRF 1-29 (CJC-1295 no DAC) (2mg)
Mod GRF 1-29 peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Mod GRF (1-29) Peptide?
Mod GRF (1-29) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It was first developed in the 1980s when studies revealed that the first 29 amino acids of GHRH possessed all of the biological roles associated with the full-length 44 residue protein. The initially designed peptide, known as GRF (1-29), is the shortest segment of GHRH, which apparently have all the properties of the full-length hormone. A different truncated synthetic form of GHRH known as Sermorelin or GRF 1-29 also has 29 amino acids. Modified GRF (1-29) undergoes alteration to include four substituted amino groups in its chain. These amino modifications appear to protect the peptide from both oxidation and degradation during manufacture and transport and in vivo. The modification further appears to increase the peptide’s binding affinity to GHRH receptors. Though GRF happens to be biologically potent like GHRH, the duration of action is restricted due to a short half-life (less than 10 minutes). As a result, researchers have modified it to enhance its half-life with better therapeutic potential. Modified GRF (1-29) is also known as Mod GRF or tetra-substituted GRF (1-29). The latter name clarifies that the modified peptide differs from GRF (1-29) as a result of changes in four of its amino acids. Modified GRF (1-29) is identical to CJC-1295 without DAC.
Modified GRF 1-29 Specifications
AKA: Mod GRF (1-29)
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
PubChem: CID 56841945
CAS Number: 863288-34-0
Modified GRF appears to mediate the same biological effects as GHRH, including muscle growth (hypertrophy), improved bone development, enhanced lipolysis, accelerated metabolism, and wound healing. Researchers also report its potential to exhibit a positive influence on the immune system and blood sugar regulation.
Mod GRF (1-29) and Cardiac Function
Research in rodent models has observed that Modified GRF and other GHRH derivatives may improve the capacity of the heart to pump blood even after a heart attack. The scientists reveal that “Various studies demonstrate that GHRH agonists promote repair of cardiac tissue, producing improvement of ejection fraction and reduction of infarct size in rats, reduction of infarct scar in swine, and attenuation of cardiac hypertrophy in mice, suggesting clinical applications.” This could be of immense potential in improving the quality of life and reducing death over the long term in patients diagnosed with cardiac failure. Modified GRF may be effective in treating pulmonary hypertension, cardiac failure, heart attack, and diverse congenital heart conditions, though research is ongoing.
Mod GRF (1-29) and the Intestine
Early studies suggested that growth hormone (GH) is beneficial for Crohn’s disease, short bowel syndrome, and other inflammatory bowel conditions. Unfortunately, the adverse effects of long-term use exceed the benefits of the hormone. Thus, researchers have looked into GHRH analogs for mediating a similar effect. Research in monkeys suggest that Mod GRF acts by binding with vasoactive intestinal peptide (VIP) receptors and therefore may improve bowel motility, as improved bowel movement is of crucial relevance in inflammatory bowel diseases associated with constipation. The researchers report that “These results suggest that the substituted GRF analog, GRF-6, likely causes the diarrheal side-effects in monkeys by interacting with the VPAC(1)-R.” The peptide appears to interact with VIPC1, present on the smooth muscle of the reproductive, gastrointestinal as well as urinary systems. These conditions trigger a great deal of morbidity and are difficult to address due to the lack of alternative medicine options.
Mod GRF (1-29) and Thyroid and Growth Hormones
Malfunctioning of the thyroid gland is often associated with concomitant issues in GH release. Studies focusing on patients suffering from hypothyroidism, treated the subjects with Modified GF to explore the above hypothesis. It has been observed that individuals who receive the thyroid replacement hormone demonstrate stronger reactions to GRF, proving a link between thyroid hormone and GH. Thus, peptides like modified GRF may contribute towards a better understanding of human physiology. Modified GRF is reported to exhibit milder side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice.
- Wehrenberg WB, Ling N. In vivo biological potency of rat and human growth hormone-releasing factor and fragments of human growth hormone-releasing factor. Biochem Biophys Res Commun. 1983 Sep 15;115(2):525-30. doi: 10.1016/s0006-291x(83)80176-4. PMID: 6414471.
- Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. doi: 10.1210/en.2019-00111. PMID: 31070727
- Ito T, Igarashi H, Pradhan TK, Hou W, Mantey SA, Taylor JE, Murphy WA, Coy DH, Jensen RT. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Peptides. 2001 Jul;22(7):1139-51. doi: 10.1016/s0196-9781(01)00436-3. PMID: 11445245.
- Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology. 1985 Jun;116(6):2643-9. doi: 10.1210/endo-116-6-2643. PMID: 2859987.
- Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clin Endocrinol (Oxf). 1986 Jun;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.